Literature DB >> 23439643

Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin.

Jop Jans1, Roger J M Brüggemann, V Christmann, Paul E Verweij, Adilia Warris.   

Abstract

Invasive Candida infections associated with medical devices are very difficult to cure without device removal. We present a case of neonatal cerebrospinal fluid shunt-associated Candida meningitis, in which removal of the device was precluded, that was successfully treated with caspofungin. Pharmacokinetic assessment of caspofungin concentrations in cerebrospinal fluid showed that exposure was adequate in the presence of a high systemic exposure. In complex cases of neonatal Candida infections involving medical devices, the addition of caspofungin might be beneficial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439643      PMCID: PMC3632945          DOI: 10.1128/AAC.02085-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.

Authors:  Priya Uppuluri; Anand Srinivasan; Anand Ramasubramanian; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.

Authors:  Shu Okugawa; Yasuo Ota; Keita Tatsuno; Kunihisa Tsukada; Satoshi Kishino; Kazuhiko Koike
Journal:  Scand J Infect Dis       Date:  2007

3.  Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.

Authors:  Aspasia Katragkou; Athanasios Chatzimoschou; Maria Simitsopoulou; Maria Dalakiouridou; Eudoxia Diza-Mataftsi; Chaido Tsantali; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

4.  EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-01-11       Impact factor: 8.067

5.  In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors:  Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

6.  EUCAST technical note on anidulafungin.

Authors:  M C Arendrup; J-L Rodriguez-Tudela; C Lass-Flörl; M Cuenca-Estrella; J P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-09-16       Impact factor: 8.067

7.  Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.

Authors:  Chi-Chung Li; Peng Sun; Yingwen Dong; Sheng Bi; Rajesh Desai; Marissa Fallon Dockendorf; Nicholas A Kartsonis; Angela L Ngai; Susan Bradshaw; Julie A Stone
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

8.  In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis.

Authors:  Sona Kucharíková; Hélène Tournu; Michelle Holtappels; Patrick Van Dijck; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

9.  Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

Authors:  Xavier Sáez-Llorens; Mercedes Macias; Padmanabha Maiya; Juan Pineros; Hasan S Jafri; Archana Chatterjee; Gloria Ruiz; Janaki Raghavan; Susan K Bradshaw; Nicholas A Kartsonis; Peng Sun; Kim M Strohmaier; Marissa Fallon; Sheng Bi; Julie A Stone; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Pharmacokinetics and safety of caspofungin in older infants and toddlers.

Authors:  Michael Neely; Hasan S Jafri; Nita Seibel; Katherine Knapp; Peter C Adamson; Susan K Bradshaw; Kim M Strohmaier; Peng Sun; Sheng Bi; Marissa Fallon Dockendorf; Julie A Stone; Nicholas A Kartsonis
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

View more
  4 in total

Review 1.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 2.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 3.  Advances in the Treatment of Mycoses in Pediatric Patients.

Authors:  Elias Iosifidis; Savvas Papachristou; Emmanuel Roilides
Journal:  J Fungi (Basel)       Date:  2018-10-11

Review 4.  Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.

Authors:  Jill King; Zoi-Dorothea Pana; Thomas Lehrnbecher; William J Steinbach; Adilia Warris
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.